VA 111913

Drug Profile

VA 111913

Alternative Names: VA 111913 TS; VA 913; VA111913

Latest Information Update: 25 Aug 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Vantia Therapeutics
  • Class Small molecules
  • Mechanism of Action Vasopressin 1a receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Dysmenorrhoea

Most Recent Events

  • 25 Aug 2015 No recent reports on development identified - Phase-II for Dysmenorrhoea in USA and United Kingdom (PO)
  • 15 Nov 2010 Vantia completes a phase II trial in dysmenorrhoea in USA and United Kingdom
  • 07 Oct 2009 Phase-II clinical trials in Dysmenorrhoea in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top